东方生物: 关于以集中竞价方式回购公司股份的方案

Core Viewpoint - The company plans to repurchase shares with an amount ranging from RMB 25 million to RMB 50 million to maintain company value and shareholder rights [1][3][4] Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 25 million and not exceed RMB 50 million [1][4] - The funding source for the repurchase will be entirely from self-owned or self-raised funds, including special loans for stock repurchase [1][8] - The maximum repurchase price is set at RMB 32.44 per share, which does not exceed 130% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6] - The repurchase will be conducted through centralized bidding and is expected to be completed within three months from the board's approval [1][5][6] Purpose and Use of Repurchased Shares - The repurchased shares will be used to maintain company value and shareholder rights, and will be sold within 12 months after the repurchase results are disclosed [1][4][13] - If the company fails to sell the shares within the stipulated time, the unsold shares will be canceled [1][4][13] Shareholder and Management Plans - The controlling shareholders and key management personnel have no plans to reduce their holdings during the repurchase period and the following three to six months [2][12] - The financial officer indicated a potential for share reduction in the future, subject to legal requirements [2][12] Implementation and Regulatory Compliance - The repurchase plan was approved by the board on June 26, 2025, and does not require further shareholder approval [3][4] - The company will adjust the repurchase terms in accordance with any changes in national policies [1][4][15] - The company has obtained a loan commitment from a bank to support the repurchase [8][10] Financial Impact - The repurchase amount will represent approximately 0.38% to 0.76% of the total share capital, depending on the final number of shares repurchased [6][7] - The total assets of the company as of March 31, 2025, were RMB 775.92 million, with a net asset value of RMB 652.18 million, indicating that the repurchase will not significantly impact the company's financial stability [10][11]